186 related articles for article (PubMed ID: 26907647)
1. The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report.
Yeo KK; HaDuong JH
J Pediatr Hematol Oncol; 2016 Aug; 38(6):489-90. PubMed ID: 26907647
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
Cherry MA; Bhardwaj H; Hopps S; Srour S; Pant S
J Oncol Pharm Pract; 2013 Sep; 19(3):261-4. PubMed ID: 23135805
[TBL] [Abstract][Full Text] [Related]
3. [Methylene blue in ifosfamide-induced encephalopathy].
Koschuth A; Späth-Schwalbe PE; Possinger K
Dtsch Med Wochenschr; 1996 Sep; 121(39):1210. PubMed ID: 8925751
[No Abstract] [Full Text] [Related]
4. Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy.
Gharaibeh EZ; Telfah M; Powers BC; Salacz ME
J Oncol Pharm Pract; 2019 Oct; 25(7):1784-1786. PubMed ID: 30348070
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of ifosfamide induced encephalopathy with methylene-blue].
Ferrero JM; Eftekari P; Largillier R; Dreyfus G; Namer M
Bull Cancer; 1995 Jul; 82(7):598-9. PubMed ID: 7549123
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case.
Müngen E; Yaman Bajin İ; Öz S; Günbey C; Anlar B; Aydin B
J Pediatr Hematol Oncol; 2022 Oct; 44(7):402-404. PubMed ID: 35536996
[TBL] [Abstract][Full Text] [Related]
7. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy.
Küpfer A; Aeschlimann C; Cerny T
Eur J Clin Pharmacol; 1996; 50(4):249-52. PubMed ID: 8803513
[TBL] [Abstract][Full Text] [Related]
8. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
9. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment with methylene blue of ifosfamide-induced central nervous system effects].
Demandt M; Wandt H
Dtsch Med Wochenschr; 1996 Apr; 121(17):575. PubMed ID: 8620831
[No Abstract] [Full Text] [Related]
11. Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer.
Ataseven E; Göktepe ŞÖ; Kantar M
J Oncol Pharm Pract; 2021 Dec; 27(8):2018-2022. PubMed ID: 33779369
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity.
Giovanis P; Garna A; Marcante M; Nardi K; Giusto M
Tumori; 2009; 95(4):545-6. PubMed ID: 19856674
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Liu YL; Tsai SH; Chang FW; Yu MH
Taiwan J Obstet Gynecol; 2010 Mar; 49(1):77-80. PubMed ID: 20466298
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide-induced encephalopathy and movement disorder.
Ames B; Lewis LD; Chaffee S; Kim J; Morse R
Pediatr Blood Cancer; 2010 Apr; 54(4):624-6. PubMed ID: 19953647
[TBL] [Abstract][Full Text] [Related]
15. Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?
Abahssain H; Moukafih B; Essangri H; Mrabti H; Meddah B; Guessous F; Fadhil FZ; Souadka A; Errihani H
J Oncol Pharm Pract; 2021 Jan; 27(1):143-149. PubMed ID: 33153383
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide induced encephalopathy in a child with osteosarcoma.
Sarbay H; Demir ÜF; Yılmaz G; Atay AA; Malbora B
J Oncol Pharm Pract; 2021 Jul; 27(5):1302-1306. PubMed ID: 33023384
[TBL] [Abstract][Full Text] [Related]
17. Evaluating risk factors for the development of ifosfamide encephalopathy.
David KA; Picus J
Am J Clin Oncol; 2005 Jun; 28(3):277-80. PubMed ID: 15923801
[TBL] [Abstract][Full Text] [Related]
18. Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy.
McDonnell AM; Rybak I; Wadleigh M; Fisher DC
J Oncol Pharm Pract; 2012 Dec; 18(4):436-9. PubMed ID: 22235061
[TBL] [Abstract][Full Text] [Related]
19. Role of thiamine in managing ifosfamide-induced encephalopathy.
Hamadani M; Awan F
J Oncol Pharm Pract; 2006 Dec; 12(4):237-9. PubMed ID: 17156595
[TBL] [Abstract][Full Text] [Related]
20. Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.
Sweiss KI; Beri R; Shord SS
Drug Saf; 2008; 31(11):989-96. PubMed ID: 18840018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
